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Abstract
Background:  Homocysteine (Hcy) and inflammatory cytokines have been linked to adverse
outcomes in persons with cardiovascular and kidney diseases and recent reports suggest that
cytokine-mediated inflammatory infiltrates may be an important contributor to the pathogenesis
the aforementioned diseases. Although some reports suggest that Hcy directly influences
inflammatory cytokine production, this proposition has not been supported by data from other
studies. The objective of the current study was to a) utilize an in vitro cellular model to identify
cytokines that may be affected by Hcy and b) examine the role of mitogen activated protein kinase
(MAPK) and phosphatidyl inositol 3- (PI3) Kinase in Hcy modulated cytokine production.
Methods: Primary rat glomerular mesangial cells (MC, passage 8 to 15), isolated by standard
sieving methodology, were exposed to Hcy (15, 50 or 100 μM) with L-cysteine (L-Cys; 100 μM)
serving as a control. An antibody array was used to identify cytokines that were modulated when
MCs were exposed to Hcy. Gene expression was assessed by quantitative RT-PCR, while western
blotting analysis was used to assess cellular protein levels in the presence and absence of inhibitors
of MAPK and PI3 Kinase. Finally, leukocyte adhesion assay was used to examine the effect of Hcy
on leukocyte adhesion to glomerular MCs that were maintained in media without, and with, kinase
inhibitors.
Results:  We identified macrophage inflammatory protein 2 (MIP-2) as a key cytokine that
manifested increases in both protein and mRNA following exposure of glomerular MC to
pathophysiologic  Hcy levels (50 μM). Further analyses revealed that Hcy-induced MIP-2 was
dependent on activation of p38 MAPK and PI3 kinase. MIP-2 enhanced leukocyte adhesion to MC
and this MIP-2-enhanced leukocyte adhesion was also dependent on activation of p38 MAPK and
PI3K. Finally, we demonstrate that leukocyte adhesion to MC is specifically inhibited by anit-MIP2
antibody.
Conclusion: The data suggest that Hcy participates in inflammatory cytokines production by
glomerular MC and that Hcy-induced MIP-2 mediates leukocyte adhesion to MC.
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Background
Elevated levels of plasma homocysteine (Hcy; ≥15 μM)
are associated with chronic kidney disease and end-stage
renal disease (ESRD) irrespective of the underlying aetiol-
ogy [1,2]. However, the pathophysiological consequences
of hyperhomocysteinemia (Hhcy) remain controversial
because, although Hhcy has consistently been associated
with morbidity and mortality, recent epidemiologic stud-
ies have produced conflicting results. In a prospective
community-based study of persons without kidney dis-
ease at study inception, over a 5-year period, chronic kid-
ney disease risk was found to increase in association with
escalating Hcy levels in both men and women [3]. The
converse has been also reported; that is, chronic kidney
disease is a direct cause of Hhcy; Hcy levels rises in direct
relationship to reduction in glomerular filtration rates
(GFR) [4,5]. Given the existence of these inconsistent
observations, the role of Hcy in progressive kidney disease
is unresolved and continues to be the focus of ongoing
clinical and basic investigations.
Notwithstanding contradictory observations, studies have
identified an association between Hcy and inflammation.
For instance, in subject aged ≥ 65 years, IL-6 and IL-1ra
cytokines were independent predictors of plasmatic Hcy
concentrations [6]. Similarly, in another study, serum Hcy
levels and C-reactive protein levels were significantly
higher in patients with stage 3 chronic kidney disease
(CKD) compared to those with stage 1 disorder [7]. In this
regard, the potential consequences of Hhcy on inflamma-
tion in the kidney have been studied by assessing the
impact of Hcy on monocyte chemoattractant protein-1
(MCP-1) expression by glomerular mesangial cells (MC)
[8]. Hcy (50 to 200 μM) induced MCP-1 protein and
mRNA levels in glomerular MC via nuclear factor kappa B
(NF-κB) activation, a process found to be mediated by
generation of oxidative stress [8].
In a related study, the same investigators observed that in
methionine-induced Hhcy rats, MCP-1 protein and
mRNA levels were increased in kidneys and that this
increase was dependent on NF-κB. The authors surmised
that these observations link Hcy-induced inflammatory
response to kidney injury and progressive kidney disease.
We have demonstrated that Hcy induces DNA damage
and apoptosis in MC. These adverse effects were depend-
ent on Hcy-induced oxidative stress and p38 MAPK activa-
tion [9]. In addition, in a separate study, we have also
documented calcium-dependent, extracellular signal-reg-
ulated kinase mediated MC proliferation in response to
Hcy [10]. These prior studies suggest that elevated levels of
Hcy may contribute to MC proliferation or apoptosis,
processes that may mediate kidney injury and contribute
to chronic kidney disease.
Given the observation that MC are able to secrete chemok-
ines in response to extracellular stimuli, it has been pro-
posed that these chemokines serve an important role of
mediating leukocyte infiltration that participate in
glomerular response to injury and in the progression of
kidney disease [11]. Indeed, in circumstances where MC
are exposed to noxious stimuli, they secrete macrophage
inflammatory protein 2 (MIP-2, also known as CXCL2)
that mediate neutrophil infiltration [12].
MIP-2 is a potent neutrophil chemotactic stimulant that is
typically secreted by macrophages in response to inflam-
mation induced by endotoxin [13]. MIP-2 is a member of
the CXC chemokine sub-family of cytokines that includes
IL-8 (CXCL8) and KC (CXCL1) among others. Structur-
ally, CXC chemokines are characterised by possessing one
amino acid residue between the first two conserved
cysteine residues. This is in contrast to the CC chemokines
(includes macrophage chemoattractant proteins [MCP] -
1, 2, 3, 4, regulated upon activation normal T cell
expressed and secreted [RANTES], MIP-1α,  β,  γ,  δ and
MIP-3α and β) in which the first two conserved cysteine
residues are adjacent [14,15]. The CXC chemokines are
capable of regulating all stages of neutrophil recruitment
(mobilization from bone marrow, tumbling and adhe-
sion to the endothelium and transmigration) to inflam-
matory or injury foci; their actions are mediated by CXC
receptors (CXCR) [16,17].
MCs are capable of producing and secreting MIP-2 and,
MC-derived MIP-2 has been demonstrated to mediate
glomerulonephritis in a rat model of the aforementioned
disorder [12]. Accordingly, the current study had two
major objectives namely a) to examine the role of Hhcy in
cytokine production by MC and b) to define some of the
signalling mechanism(s) that may participate in this proc-
esses. In particular, given our earlier observation that MC
response to extracellular Hcy involves activation of MAPK,
the role of MAPK activation in MIP-2 production by MC
was evaluated.
Methods
Cell Culture
Sprague-Dawley rat MCs were isolated by the sieving
method [18]. The cells were cultured in Dulbecco's Modi-
fied Eagle's Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) (Invitrogen, CA), streptomycin
(100 μg/ml), penicillin (100 IU/ml) and 2 mM glutamine
at 37°C in 95% air/5% CO2. Cells from passage 8-15 were
used throughout these studies. All other chemicals were
obtained from Sigma-Aldrich (St. Louis, MO) unless oth-
erwise indicated.
Cytokine Antibody Array
A rat cytokine antibody array (Cat# R0608001; RayBio-
tech Inc., Norcross, GA, USA) was employed to assessJournal of Inflammation 2009, 6:27 http://www.journal-inflammation.com/content/6/1/27
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cytokine production by MC following exposure to Hcy.
The protocol was executed according to the manufac-
turer's specifications. Briefly, MCs (106  cells/100 mm
dish) were initially seeded unto plastic dishes in DMEM
supplemented with FBS (10%). Subsequently, cultures
were serum-starved overnight (DMEM supplement with
0.5% FBS), followed by incubation in medium (DMEM
supplement with 0.5% FBS) with L-cysteine (L-Cys; 100
μM) or Hcy (50 μM) for 24 hours at 37°C. The cells were
harvested and cellular protein was prepared from lysates
as described below. Protein form lysates (50 μg) was used
to determine chemokine production using rat cytokine
antibody array membranes according to the manufac-
turer's protocol. Membranes were initially blocked (30
minutes/room temperature), followed by exposure to cell
lysate (2 hours/room temperature). After washing, expo-
sure to biotin conjugated cytokine antibody and HRP-
conjugated streptavidin, cytokines were detected using
standard chemiluminescent methods (please see section
below on 'Determination of MIP-2 protein'). The proce-
dure was performed three times.
Determination of MIP-2 expression by Mesangial Cells
MC were initially seeded unto plastic dishes (1 × 106 cells/
100 mm dish) in DMEM supplemented with 10% FBS.
Subsequently, cultures were serum-starved overnight, fol-
lowed by incubation with L-cysteine (L-Cys; 100 μM) or
Hcy (15 μM, 50 μM and 100 μM) for 24 hours at 37°C.
Cells were harvested and total RNA was isolated by estab-
lished methods [19]. Following cDNA synthesis (qPCR
cDNA Synthesis Kit Cat# 600559, Stratagene, La Jolla,
CA), qPCR was performed using an iQ-SYBR Green kit
(Bio-Rad, Hercules, CA). MIP-2 expression was assessed
using the following primers: sense - AACAAAC TGCACCC
AGGAAG and antisense  - GAGCTGGCCAATGCATATCT.
GAPDH served as control; expression of the latter was
determined using the following primers:- sense AGGTCG-
GTGTGAACGGATTTG and antisense  - TGTAGACCATG-
TAGTTGAGGTCA. Gene expression was quantified by the
standard curve method [20,21].
Detection of MIP-2 Protein in Mesangial cells
Cultures were serum-starved overnight, followed by incu-
bation with L-Cys (100 μM) or Hcy (15 μM, 50 μM and
100 μM) for 24 hours at 37°C. Subsequently, cells were
washed with phosphate buffered saline (PBS; 4°C) and
harvested under non-denaturing conditions by incuba-
tion (4°C/5 minutes) with lysis buffer (20 mM Tris, pH
7.4; 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1%Triton
X-100; 1 mM-glycerolphosphate, 1 mM Sodium
Orthovanadate; 1 μg/ml leupeptin; 1 mM phenyl methyl-
sulphonyl flouride). Following centrifugation (14,000 ×
g, 4°C, 10 minutes), the supernatant was transferred to a
fresh microcentrifuge tube and the protein concentration
was measured with Bio-Rad protein assay reagent (Bio-
Rad, Hercules, California, USA).
Protein was separated on a SDS-PAGE gel (4-20%). After
electroblotting to a nitrocellulose membrane (Protran,
Schleicher and Schuell, Keene, NH), membranes were
incubated (room  temperature/3 hours) with 25 ml of
blocking buffer (1× Tris buffered saline, TBS; 0.1% Tween-
20 containing 5% w/v non-fat dry milk) and then over-
night at 4°C with rabbit polyclonal macrophage inflam-
matory  protein-2 antibody (1:2000, cat #ab9777; Abcam,
Cambridge MA) in 20 ml of antibody dilution buffer (1×
TBS, 0.1% Tween-20) with gentle rocking. Membranes
were washed 3 times with TTBS and then incubated with
HRP-conjugated anti-rabbit secondary antibody
(1:10,000, Cell Signalling Technology) in 20 ml of anti-
body dilution buffer (1× TBS, 0.1% Tween-20/60 min-
utes/room temperature). After three further TBS washes,
the membrane was incubated with ECL Chemilumines-
cence Reagent (Amersham Biosciences) and then exposed
to X-ray film (X-OMAT, Kodak, Rochester NY). Immune
complexes were removed from the membrane by treat-
ment with stripping buffer (100 mM 2-mercaptoethanol,
2% SDS, 62.5 mM Tris-HCl [pH6.7]; 50°C; 30 minutes).
Subsequently, protein loading was assessed by re-blotting
with anti-actin antibody (1:12,000 Sigma-Aldrich, St.
Louis, MO.) and an HRP-conjugated anti-rabbit second-
ary antibody (1:25,000; Cell Signalling Technology). Pro-
tein bands were quantified using BioRad Quantity One
software package.
In order to study the effect of kinase inhibitors on MIP-2,
MCs were incubated in the presence of Hcy (50 μM) with
or without inhibitors U0126 (p42/44 MAPK inhibitor; 10
μM), SB203580 (p38MAPK inhibitor; 10 μM) and
LY294002 (PI3 Kinase inhibitor; 10 μM) for 24 h at 37°C.
Subsequently, cells were washed with PBS (4°C) and har-
vested under non-denaturing conditions by incubation
(4°C/5 minutes) with lysis buffer as described above.
MIP-2 protein was quantified after detection by western
blot as described above.
Immunofluorescence Microscopy for MIP-2
MCs (104 cells/well) were initially plated onto sterile two-
chambered slides (product no. 154461, Nalge Nunc,
Rochester, NY) exactly as described for other experiments
above. After incubation (37°C; 24 hours) in the presence
of Hcy (50 μM) with or without kinase inhibitors, cells
were washed (thrice with 1× PBS) and fixed (3.7% formal-
dehyde, 10 minutes, ambient temperature). Following
PBS washes (thrice), cells were permeabilized (0.1%Tri-
ton X-100, 4°C, for 2 minutes), washed again with PBS
and incubated with blocking solution (1% BSA; 1% goat
serum in PBS) for 60 minutes at room temperature.
The cells were subsequently incubated with rabbit poly-
clonal MIP-2 antibody (4°C; 24 hours) constituted in
blocking solution. Following PBS washes (thrice), cells
were incubated (60 minutes; ambient temperature; light-Journal of Inflammation 2009, 6:27 http://www.journal-inflammation.com/content/6/1/27
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protection) with Alexa-fluor 555-conjugated goat anti-
rabbit secondary antibody (Molecular Probes/Invitro-
gen). The cells were washed with PBS and slips were
mounted onto glass slides using mount media anti-fade
mixture and stored (4°C, light-protected) until fluores-
cence microscopy laser scanning was performed using a
Zeiss Axioplan 2 Imaging System (Carl Zeiss MicroImag-
ing Inc., Thornwood, NY, USA).
Western Blot analysis of p38MAPK and p85 PI3K 
phosphorylation
Cultures were serum-starved overnight prior to the addi-
tion of L-Cys (100 μM) or Hcy (15 μM, 50 μM and 100
μM). Subsequently, cells were washed with PBS (4°C) and
harvested under non-denaturing conditions by incuba-
tion (4°C/5 minutes) with lysis buffer as described above.
Western blot was performed as described above. The
immuno-blot membrane was incubated with anti-pp85
or anti-pp38 MAPK at 1:1000 dilution (overnight; 4°C),
followed by incubating with HRP-conjugated anti-rabbit
secondary antibody at 1:2000 for 60 minutes at room
temperature. The membrane was reprobed with anti-p85
or anti-p38MAPK (dilution 1:1000), followed by incubat-
ing with HRP-conjugated anti-rabbit secondary antibody.
The bands of pp85PI-3 K and pp38MAPK were normal-
ized with p85 PI-3K and p38MAPK respectively for analy-
sis using BioRad Quantity One package.
Mouse Leukocyte adhesion assay
The assay was used to evaluate leukocyte-MC adhesion in
the presence of increasing doses of Hcy, and Hcy (50 μM)
with kinase inhibitors (SB203580 and LY294002) and
pAb MIP-2. MCs were initially plated at a density of
10,000 cells/well in 24-well tissue culture plate. Following
overnight serum starvation MCs were incubated (37°C;
24 hours) in the presence of Hcy (50 μM) with or without
inhibitors 10 μM SB203580 (p38MAPK inhibitor) and 10
μM LY294002 (PI3 Kinase inhibitor).
Cell adhesion assay was performed as per manufacturer's
protocol (Vybrant Cell Adhesion Assay Kit; Cell Biolabs
Inc., San Diego, CA). In brief, leukocytes were isolated
from blood collected from anaesthetized mice and pre-
pared as described in the manufacturer's protocol (Easy
lyse whole blood Erythrocyte Lysing Kit; Leinco Technol-
ogies Inc. St. Louis, MO). Subsequently, isolated leuko-
cytes were labelled with Calcein AM, MCs were washed
with PBS, followed by addition of labelled leukocyte cell
suspension (13,000 cells/well) in DMEM to each well.
The co-culture was incubated (2 hour, 37°C), and follow-
ing this period, non-adherent cells leukocytes were
removed by gently washing with PBS, followed by addi-
tion of 300 μl PBS to each well. Fluorescence from leuko-
cytes bound to mesangial cells was determined by
spectrophotometry (Wallac Victor, 1420 Multilabel coun-
ter, Perkin Elmer). The percentage of bound leukocytes to
un-stimulated MC represented 100% and was compared
to other conditions.
For neutralization experiments, MC stimulated with 50
μM Hcy overnight were washed with PBS. The cells were
then incubated with 5 μg/ml pAb MIP-2 prepared in
DMEM for 3 hours at 37°C, before incubating with
labelled leukocytes.
Statistical Analyses
In each series of experiment, differences between means
were analyzed by Student's t test using Instat Statistical
software (GraphPad Inc.San Diego, CA). Differences were
considered significant at p < 0.05.
Results
Homocysteine influences cytokine levels in mesangial cells
Previous studies have suggested an association between
Hcy and expression of inflammatory cytokines [12]. We
sought to assess this relationship in the context of glomer-
ular disease by utilising cytokine antibody array to register
changes in cytokine levels. MC were exposed to patho-
physiologic Hcy concentration (50 μM) that has been pre-
viously shown to modulate MC behaviour [10]. The
results (table 1) revealed that several cytokines were sig-
nificantly affected by this manoeuvre, including TIMP-1,
MIP-2, interferon gamma and fractalkine. MIP-2 influ-
ences leukocyte migration and has been shown to mediate
inflammatory infiltration in glomerular disease [22,23].
Accordingly, we chose to explore the influence of Hcy on
Table 1: Antibody Array analysis of changes in cytokine levels in 
mesangial cells following exposure to DL-homocysteine (50 μM).
Cytokine Change P-value
TIMP-1 1.9 0.02
TNFα 1.1 NS
β-NGF 1.1 NS
MIP-3α 1N S
MCP-1 1.2 NS
IL-6 1.1 NS
IL-10 1.1 NS
CINC-2 (MIP-2) 2.4 0.01
IFN-γ 0.5 0.045
Fractalkine 0.2 0.02
GM-CSF 0.4 0.048
LIX 0.9 NS
Values are expression relative to levels in cells cultured in glucose (5.6 
mM) with 100 μM L-cysteine but lacking homocysteine; n = 3. 
Abbreviations: TIMP-1 - tissue inhibitor of metalloproteinases 1; TNFα- 
tumor necrosis factor alpha; β-NGF - beta nerve growth factor, MIP-
3α- macrophage inflammatory protein 3 alpha; MCP-1 - monocyte 
chemotactic protein 1; IL-6 - interleukin 6; IL-10 - interleukin 10; 
CINC-2 - cytokine-induced neutrophil chemoattractant 2 (also 
known as macrophage inflammatory protein 2 and GROβ [growth-
regulated gene product beta]); IFN-γ - interferon beta; GM-CSF - 
granulocyte monocyte colony stimulating factor; LIX - 
Lipopolysaccharide (LPS)-induced chemokine.Journal of Inflammation 2009, 6:27 http://www.journal-inflammation.com/content/6/1/27
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MIP-2 and to relate the observations to leukocyte interac-
tion with glomerular MC in an in vitro assay system.
Homocysteine induces MIP-2 expression and increases 
MIP-2 protein
Initially we determined the influence of variable Hcy con-
centrations (15, 50 and 100 μM) on MIP-2 expression by
qRT-PCR. The results (figure 1A) indicated a significant
impact on expression at 50 and 100 μM. Another sulphur-
containing amino acid (L-cysteine), that is structurally
similar to DL-Hcy [24] did not influence expression.
Hence changes in MIP-2 expression can be attributed to
an effect specific to Hcy, rather than to structural similari-
ties with L-Cys. Subsequently, the expression of MIP-2
induced by Hcy in MC was quantified by western blot
analysis. In line with the expression data, Hcy significantly
increased MIP-2 protein levels in MC (figure 2B). Of note,
MIP-2 expression increased 2.5 fold at 50 μMHcy, com-
pared to expression at 100 μM L-Cys (p < 0.05). MIP-2 lev-
els did not increase further when Hcy concentration was
increased to 100 μM.
Homocysteine induced MIP- 2 requires p38MAPK and 
PI3kinase but not P42/44 MAPK Signaling
MIP-2 induction has been reported to be MAPK and PI-3
Kinase dependent [25]. Hence, we investigated role of
MAPK and PI-3 Kinase in MIP-2 expression induced by
Hcy. Hcy-induced MIP-2 was significantly attenuated (p <
0.05) by a PI-3 Kinase inhibitor (LY294002) and by an
inhibitor of a p38MAPK (SB203580). In contrast, use of a
p42/44 MAPK inhibitor (U0126) did not significantly
alter Hcy-induced MIP-2 (figure 2A).
Immunohistochemistry was employed as another analyt-
ical tool to examine the effect of Hcy on mesangial MIP-2.
Cells were exposed to Hcy (50 μM/0.5% FBS), in the
absence and presence of inhibitors to p38MAPK
(SB203580; 10 μM) and PI3 Kinase (LY294002; 10 μM).
MIP-2 expression in medium supplemented with FBS
(0.5%) and L-Cys (100 μM) represented control condi-
tions. As revealed in figure 2, panel C, the expression of
MIP-2 was increased by Hcy (50 μM) compared to control
(panel B). Hcy-induced of MIP-2 was abolished by
LY294002 (PI3 Kinase inhibitor; panel D) and SB203580
(p38MAPK inhibitor; panel E). These results suggest that
Hcy induced expression of MIP-2 in MC was mediated by
p38MAPK and PI-3 K signalling pathways and are consist-
ent with the results derived from Western blotting analy-
sis.
Hcy activates p85 PI-3 Kinase and p38MAPK in mesangial 
cells
In an effort to corroborate the observations related to
blunting of the effect of Hcy on MIP-2 by inhibitors of PI3
Kinase and p38MAPK, western blotting analyses was
employed to determine levels of activated (phosphor-
ylated) p38MAPK and PI3 Kinase in MC exposed to ele-
vated levels of extracellular Hcy.
Hcy induced time dependent increases in p38 MAPK
phosphorylation between 10 and 30 minutes. Phosphor-
ylation of p38 MAPK decreased significantly at 60 min-
utes as compared to that for 10 minutes (figure 3A).
Similarly, Hcy induced p85 PI3K phosphorylation in a
time dependent manner. Phosphorylation of p85 PI-3K
significantly increased at 20 minutes (2.25 fold as com-
Homocysteine induces MIP- 2 mRNA (A) and Protein (B) in  mesangial cells Figure 1
Homocysteine induces MIP- 2 mRNA (A) and Pro-
tein (B) in mesangial cells. MCs were incubated with L-
cysteine (100 μM) or Hcy (15 μM, 50 μM and 100 μM) for 24 
hours at 37°C in 100 mm dish. To determine expression (A), 
following trypsinization of cell monolayers, total RNA was 
isolated by the single-step method [19]. Subsequently, qRT-
PCR was performed as described in text. Total protein was 
extracted from harvested cells under non-denaturing condi-
tions using lysis buffer. MIP-2 protein levels (B) were 
detected by western blot. Results are representative of three 
separate experiments. Protein bands were quantified (Quan-
tity One software, Bio-rad) and levels were represented as 
percentage response of control (100 μM L-Cysteine). Data 
represent mean ± SEM from three separate experiments. *p 
< 0.05.
B
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Homocysteine-induced MIP- 2 is mediated by p38MAPK and PI3 kinase Figure 2
Homocysteine-induced MIP- 2 is mediated by p38MAPK and PI3 kinase. MCs were incubated (24 hours; 37°C) in 
the presence of Hcy (50 μM) with or without inhibitors U0126 (p42/44 MAPK inhibitor; 10 μM), SB203580 (p38MAPK inhibi-
tor; 10 μM) and LY294002 (PI3 Kinase inhibitor; 10 μM). Cells were washed with PBS (4°C) and harvested using lysis buffer 
under non-denaturing conditions. MIP-2 protein was detected by western blot (A). Subsequently, protein bands were quanti-
fied as before. Results are representative of three separate experiments. Data represent mean ± SEM; *p < 0.05 indicate signif-
icant inhibition compared to 50 μM Hcy. (B to E) MCs were incubated (24 hours; 37°C) in the presence of Hcy (50 μM) with 
or without kinase inhibitors in Lab-Tek II dual chamber slides (Nalge Nunc, Naperville, IL, USA). The fixed MCs were immuno-
stained with rabbit polyclonal GRO beta antibody followed by Alexa-Fluor 555 conjugated anti-rabbit antibody as described in 
the method. Nuclei were stained with DAPI. Panel B: L-Cys [100 μM], Panel C: Hcy [50 μM]; Panel D: Hcy [50 μM] + 
LY294002 [10 μM]; Panel E: Hcy [50 μM] + SB203580 [10 μM]. Panels are representative of 3 separate experiments.
L-Cys (100μM) Hcy (50μM)
Hcy + SB203580 Hcy + LY294002Journal of Inflammation 2009, 6:27 http://www.journal-inflammation.com/content/6/1/27
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pared with levels at the initiation of the study). At 30 min-
utes, p85 PI-3K phosphorylation decreased as compared
with 20 minutes (figure 3B).
MIP-2 Modulates Leukocyte cell adhesion to mesangial 
cells
Hcy-induced leukocyte adhesion to MC was determined
by cell adhesion assay following incubation of with Hcy;
L-Cys (100 μM) represented control condition. L-Cys
(100 μM) did not have a significant effect on leukocyte
adhesion to MC whereas Hcy induced dose dependent
increase in leukocyte adhesion to mesangial cells. Leuko-
cyte adhesion increased significantly up to 1.8 fold (P <
0.02) at 50 μM Hcy compared with control condition (fig-
ure 4A).
SB203580 and LY294002 treated MC was employed to
determine the role of p38MAPK and PI-3K in MIP-2 medi-
Hcy increases phosphorylation of p38MAPK (A) and p85 PI3  kinase (B) Figure 3
Hcy increases phosphorylation of p38MAPK (A) and 
p85 PI3 kinase (B). Mesangial cells were serum-starved 
overnight prior to exposure to medium containing L-cysteine 
(100 μM) or Hcy (15 μM, 50 μM and 100 μM). Cells were 
washed with PBS (4°C) and harvested using lysis buffer under 
non-denaturing conditions. Total p38 MAPK, total p85 PI-3K, 
phosphorylated p38 MAPK and phosphorylated p85 PI-3 
Kinase expression was detected by western blot as described 
in methods. Protein bands were quantified and the ratios of 
pp38MAPK/p38MAPK and pp85/p85 were represented as 
fold-changes compared to t=0. Panel depict representative 
blot of three separate experiments performed in duplicates; 
values are expressed as mean ± SEM; *p < 0.02; #p < 0.05.
A
B
Hcy-induced leukocyte cell adhesion to mesangial cells is  abrogated by p38MAPK and PI-3 Kinase inhibitors (A) and by  anti-MIP2 antibody (B) Figure 4
Hcy-induced leukocyte cell adhesion to mesangial 
cells is abrogated by p38MAPK and PI-3 Kinase inhib-
itors (A) and by anti-MIP2 antibody (B). MC were incu-
bated (24 hours/37°C) in presence of Hcy (50 μM) with or 
without inhibitors SB203580 (p38MAPK inhibitor; 10 μM) or 
LY294002 (PI3 Kinase inhibitor; 10 μM) or in the presence of 
pAb MIP-2 (5 μg/ml) B. L-Cys (100 μM) was used as a con-
trol. Cell adhesion assay was performed as described in 
method. The data represent mean ± SEM from three sepa-
rate experiments; *p < 0.05; #p < 0.02.Journal of Inflammation 2009, 6:27 http://www.journal-inflammation.com/content/6/1/27
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ated leukocyte adhesion to these glomerular cells. As
revealed (figure 4A), LY294002 (PI-3 kinase inhibitor)
and SB203580 (p38MAPK inhibitor) blocked leukocyte
adhesion induced by 50 μM Hcy (P < 0.05). Blocking anti-
body against MIP-2 (5 μg/ml) confirmed the functional
role of MIP-2 in Hcy-induced leukocyte adhesion to MC.
Hcy (50 μM) induced leukocyte adhesion to MC was sig-
nificantly blocked up to 3 fold by MIP-2 antibody (p <
0.01) (figure 4B).
Discussion
MIP-2 is a C-X-C chemokine, known to recruit neu-
trophils [26] and studies suggest that neutrophil recruit-
ment may bear relevance to the development and
progression of glomerular diseases. The initial indication
that MIP-2 may participate in glomerular disease arose
from observations that isolated glomeruli and MC pro-
duced MIP-2 in response to immune complexes [27]. Sub-
sequently, in another in vivo rat model of
mesangioproliferative glomerulonephritis (MPGN),
glomerular nitric oxide (NO) was shown to be capable of
inducing MIP-2 expression, which in turn lead to neu-
trophil recruitment [12]. Kidney disease is associated with
increases in plasma Hcy [28] and Hcy induces MCP-1 pro-
duction by glomerular MC [8]. In order to identify
cytokines whose expression may be increased by Hcy, we
initially employed antibody array approach to evaluate
cytokine production by MC exposed to pathophysiologic
levels of Hcy.
Our initial observation (table 1) was that elevated extra-
cellular Hcy increased the levels of cytokines, TIMP-1 (1.9-
fold) and MIP-2 (2.4-fold). For another cytokine, MCP-1
there was a 20 percent increase in protein levels, but this
was not statistically significant. Other studies have dem-
onstrated a 20 to 40 percent increase in MCP-1 by MC [8]
and hepatocytes [29] exposed to comparable concentra-
tions of Hcy. Hence, our observations are similar to the
aforementioned reports, but in the current study, Hcy-
induced MCP-1 changes were not significant. In contrast,
the observations for TIMP-1 are consistent with earlier
studies [30,31], while data relating to induction of MIP-2
by Hcy have not been previously reported. Accordingly,
we explored the influence of Hcy on MIP-2 expression in
MC and examined potential signalling mechanism(s) that
may mediate this process.
In support of the antibody array data (table 1), we
observed that in MC exposed to Hcy there was a signifi-
cant increase in MIP-2 expression and protein with
changes occurring at Hcy concentrations of 50 μM and
100 μM respectively. These observations are in line with
those that have been reported for other cellular processes
that are affected Hcy [9,10]. Subsequently, we chose to
examine downstream signaling that may be involved in
this effect of Hcy on MIP-2 expression in MC. In an earlier
report, hypoxia-induced MIP-2 expression in macro-
phages was shown to be dependent on p42/44 MAPK and
PI-3 kinase pathways [25]. In another study, TNF-α
induced MIP-2 in cultured mouse astrocytes was mediated
via both p42/44 MAPK and p38 MAPK [32]. Accordingly,
we studied the impact of inhibitors of p42/44 MAPK, p38
MAPK and PI3 Kinase on Hcy-induced MIP-2 in MC.
Indeed, we observed that Hcy-induced MIP-2 expression
was inhibited by PI-3 kinase inhibitor (LY294002) and
p38MAPK inhibitor (SB203580), but was unaffected by
p42/44 MAPK inhibitor (U0126) (figure 2). Thus, our
observations are consistent with earlier reports demon-
strating that MIP-2 is regulated by specific kinases [33,34].
The failure to demonstrate a role for p42/44 MAPK signal-
ling in Hcy-induced MIP-2 in the current study may be
related to the type of cells be studied.
Our earlier study revealed that Hcy activates p38MAPK
[9]. Accordingly, we examined the effect of Hcy on phos-
phorylation of p38MAPK and p85 (catalytic subunit of
PI3 Kinase). As revealed in figure 3, Hcy induced time-
dependent increases in phosphorylated species of p38
MAPK and p85 subunit of PI3 Kinase in MC. Vascular
smooth muscle cells (phenotypically related to MC) man-
ifest MAPK- and PI3-K-dependent increases in MMP-2
synthesis upon exposure to Hcy [35]. Other studies have
identified a role for MAPK activation in mediating MIP-2
production by renal tubules and peritoneal macrophages
[33,34]. Although the stimuli and cell type are different,
the observations in the current study relating to Hcy-
induced p38MAPK and PI3 Kinase activation are consist-
ent with those reported in other studies.
Leukocyte infiltration and subsequent interstitial inflam-
mation are emerging as key features of various glomerular
diseases [11,36]. These observations have been validated
in various modular systems [37-39]. In order to determine
potential consequence(s) of changes in Hcy-induced MIP-
2 expression, we studied leukocyte adhesion to MC using
an in vitro protocol. 'In this regard, the initial observation
was that Hcy increased leukocyte binding to MC (p <
0.05) while L-Cys was without effect (figure 4A). Further-
more, inhibition of p38MAPK and PI3K activation abro-
gated Hcy-induced leukocyte bound to MC (figure 4A).
Finally, we were able to validate that MIP-2 mediated leu-
kocyte adhesion to MC by demonstrating that polyclonal
MIP-2 antibody (5 μg/ml) was capable of blocking leuko-
cyte adhesion to MC pre-incubated with Hcy (50 μM).
Conclusion
The current study reveals that Hcy induces MIP-2 expres-
sion in MC and that this effect is dependent on both PI-3
Kinase and p38MAPK activation. Furthermore, MIP-2
may be important in PI-3 Kinase- and p38MAPK-depend-Journal of Inflammation 2009, 6:27 http://www.journal-inflammation.com/content/6/1/27
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ent leukocyte adhesion to MC. The results highlight a link
between MC production of MIP-2 and its potential role in
leukocyte adhesion to MC. This is pertinent to kidney dis-
ease because elevated plasma Hcy is a hallmark of progres-
sive kidney disease and endstage kidney failure. Future in
vitro and in vivo studies are required to further ascertain
the consequences of Hcy-induced MIP-2 expression in
glomerular MC.
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